Nigel Armstrong

York, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Newborn screening for severe combined immunodeficiency in the NHS newborn blood spot screening programme: a systematic review.

Newborn screening for severe combined immunodeficiency in the NHS newborn blood spot screening programme: a systematic review.

Journal: Health technology assessment (Winchester, England)

Published: June 16, 2026

NICE Appraisals of Relugolix-CT and Linzagolix for Endometriosis Symptom Management: Commentary on Clinical and Economic Uncertainties.

NICE Appraisals of Relugolix-CT and Linzagolix for Endometriosis Symptom Management: Commentary on Clinical and Economic Uncertainties.

Journal: PharmacoEconomics

Published: December 23, 2025

Accuracy and clinical effectiveness of fetal growth monitoring strategies for the prediction of small for gestational age at birth: a systematic review and meta-analysis.

Accuracy and clinical effectiveness of fetal growth monitoring strategies for the prediction of small for gestational age at birth: a systematic review and meta-analysis.

Journal: Health technology assessment (Winchester, England)

Published: December 08, 2025

Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor.

Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor.

Journal: PharmacoEconomics

Published: November 20, 2025

Subgroup Modelling and Use of External Evidence in Precision Oncology Appraisals: An External Assessment Group Perspective on the NICE Single Technology Appraisal of Zolbetuximab for Untreated CLDN18.2-Positive HER2-Negative Unresectable Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma.

Subgroup Modelling and Use of External Evidence in Precision Oncology Appraisals: An External Assessment Group Perspective on the NICE Single Technology Appraisal of Zolbetuximab for Untreated CLDN18.2-Positive HER2-Negative Unresectable Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma.

Journal: PharmacoEconomics

Published: November 17, 2025

Reply to Comment on "Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective".

Reply to Comment on "Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective".

Journal: PharmacoEconomics

Published: September 26, 2025

Flexibility in the Modelling of Comparative Effectiveness in the Absence of Head-to-Head Comparisons in the NICE Single Technology Appraisal of Fenfluramine for Treating Seizures Associated with Lennox-Gastaut Syndrome: An External Assessment Group Perspective.

Flexibility in the Modelling of Comparative Effectiveness in the Absence of Head-to-Head Comparisons in the NICE Single Technology Appraisal of Fenfluramine for Treating Seizures Associated with Lennox-Gastaut Syndrome: An External Assessment Group Perspective.

Journal: PharmacoEconomics

Published: September 25, 2025

Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective.

Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective.

Journal: PharmacoEconomics

Published: June 25, 2025

When Evidence Falls Short-Belzutifan for Treating Tumours Associated with von Hippel-Lindau Disease: An External Assessment Group Perspective on a NICE Single Technology Appraisal.

When Evidence Falls Short-Belzutifan for Treating Tumours Associated with von Hippel-Lindau Disease: An External Assessment Group Perspective on a NICE Single Technology Appraisal.

Journal: PharmacoEconomics

Published: April 21, 2025

A cloud-based medical device for predicting cardiac risk in suspected coronary artery disease: a rapid review and conceptual economic model.

A cloud-based medical device for predicting cardiac risk in suspected coronary artery disease: a rapid review and conceptual economic model.

Journal: Health technology assessment (Winchester, England)

Published: July 18, 2024

Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective.

Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective.

Journal: PharmacoEconomics

Published: April 30, 2024

Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective.

Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective.

Journal: PharmacoEconomics

Published: April 07, 2024

Showing 1-12 of 73

Last Updated: 09/26/2026